(Q30869048)

English

Therapeutic strategies for relapsing-remitting multiple sclerosis: a special focus on reduction of grey matter damage as measured by brain atrophy

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

1 reference

Europe PubMed Central

Therapeutic strategies for relapsing-remitting multiple sclerosis: a special focus on reduction of grey matter damage as measured by brain atrophy (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

0 references

relapsing-remitting multiple sclerosis

1 reference

based on heuristic

inferred from title

Alberto Gajofatto

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25391525%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Maria Donata Benedetti

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25391525%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

author name string

Massimiliano Calabrese

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25391525%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

publication date

13 November 2014

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25391525%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25391525%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25391525%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

1417-1428

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25391525%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Multiple sclerosis

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

The immunopathology of multiple sclerosis: an overview

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Axonal transection in the lesions of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Measurement and clinical effect of grey matter pathology in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Basal ganglia and frontal/parietal cortical atrophy is associated with fatigue in relapsing—remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Age at disability milestones in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

The changing clinical course of multiple sclerosis: a matter of gray matter

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Inflammatory cortical demyelination in early multiple sclerosis

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

B-cell enrichment and Epstein-Barr virus infection in inflammatory cortical lesions in secondary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Demyelinated neocortical lesions in marmoset autoimmune encephalomyelitis mimic those in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Cortical lesion load associates with progression of disability in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Cortical lesions in primary progressive multiple sclerosis: a 2-year longitudinal MR study

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Inflammatory demyelination and neurodegeneration in early multiple sclerosis

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Gray matter involvement in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Long-term clinical outcome of primary progressive MS: predictive value of clinical and MRI data

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Evidence of early cortical atrophy in MS: relevance to white matter changes and disability

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

The relationship between diffuse axonal damage and fatigue in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Azathioprine in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Role of immunosuppressive therapy for the treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Mitoxantrone induces natural killer cell maturation in patients with secondary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Interferon-β1a protects neurons against mitochondrial toxicity via modulation of STAT1 signaling: electrophysiological evidence.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Interferon β for secondary progressive multiple sclerosis: a systematic review

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Effects of glatiramer acetate and interferon-beta on neurodegeneration in a model of multiple sclerosis: a comparative study

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Neuroprotection with glatiramer acetate: evidence from the PreCISe trial

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Neuropsychologic status in multiple sclerosis after treatment with glatiramer

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis--a prospective, non-randomized pilot study.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Teriflunomide and its mechanism of action in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Randomized trial of oral teriflunomide for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Placebo-controlled trial of oral laquinimod for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

The CD52 antigen and development of the CAMPATH antibodies

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Clinical, MRI, and CSF markers of disability progression in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Clinical impact of early brain atrophy in clinically isolated syndromes

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.979794

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30869048&oldid=1975236827"